Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
1992-7-24
|
pubmed:abstractText |
In the present study we have examined the interaction between the selective cholecystokinin (CCK)A and CCKB receptor antagonists, devazepide and L365-260 on morphine conditioned place preference (CPP). Using an unbiased procedure, morphine (1.5 mg/kg) produced a reliable CPP which was observed irrespective of the conditioning compartment type. Pretreatment with devazepide (0.001-0.01 mg/kg s.c.) produced a dose related attenuation of this response. At higher doses (0.1-1 mg/kg) this antagonism became variable and dependent on the training compartment with blockade only observed when conditioning was to the white/rough textured environment. This profile has also been reported for the serotonin (5-HT)3 receptor antagonist ondansetron. The CCKB antagonist L365-260 (0.000001-0.01 mg/kg) failed to antagonize the morphine CPP, if anything a mild potentiation was observed. To study this further we examined the interaction between L365-260 (0.01 mg/kg) and a subthreshold dose of morphine (0.3 mg/kg). At these doses neither drug elicited CPP, however when co-administered a significant CPP was recorded. Finally, L365-260 at 1 mg/kg induced a mild but significant CPP when administered alone. These results suggest a differential role of CCK receptor subtypes on reward-related behaviour and complement previous studies suggesting bimodal effects of CCK systems on mesolimbic dopamine function.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepinones,
http://linkedlifedata.com/resource/pubmed/chemical/Devazepide,
http://linkedlifedata.com/resource/pubmed/chemical/L 365260,
http://linkedlifedata.com/resource/pubmed/chemical/Morphine,
http://linkedlifedata.com/resource/pubmed/chemical/Naloxone,
http://linkedlifedata.com/resource/pubmed/chemical/Phenylurea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cholecystokinin,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium Chloride
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-8993
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
14
|
pubmed:volume |
572
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
208-15
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1611514-Animals,
pubmed-meshheading:1611514-Benzodiazepinones,
pubmed-meshheading:1611514-Choice Behavior,
pubmed-meshheading:1611514-Conditioning, Operant,
pubmed-meshheading:1611514-Devazepide,
pubmed-meshheading:1611514-Male,
pubmed-meshheading:1611514-Morphine,
pubmed-meshheading:1611514-Naloxone,
pubmed-meshheading:1611514-Phenylurea Compounds,
pubmed-meshheading:1611514-Rats,
pubmed-meshheading:1611514-Rats, Inbred Strains,
pubmed-meshheading:1611514-Receptors, Cholecystokinin,
pubmed-meshheading:1611514-Sodium Chloride
|
pubmed:year |
1992
|
pubmed:articleTitle |
Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists.
|
pubmed:affiliation |
Clinical Psychopharmacology Program, Addiction Research Foundation, Toronto, Ontario, Canada.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|